You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Litigation Details for Genus Lifesciences Inc. v. Lannett Company, Inc. (D. Del. 2020)

✉ Email this page to a colleague

« Back to Dashboard

Genus Lifesciences Inc. v. Lannett Company, Inc. (D. Del. 2020)

Docket	⤷ Sign Up	Date Filed	2020-06-08
Court	District Court, D. Delaware	Date Terminated	2021-10-20
Cause	35:1 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	Plaintiff	Referred To
Parties	LANNETT COMPANY, INC.
Patents	10,016,407; 10,149,843; 10,231,961; 10,413,505; 10,420,760; 9,867,815
Attorneys	Luke M. Reilly
Firms	Farnan LLP
Link to Docket	External link to docket

Small Molecule Drugs cited in Genus Lifesciences Inc. v. Lannett Company, Inc.

The small molecule drugs covered by the patents cited in this case are ⤷ Sign Up and ⤷ Sign Up .

Details for Genus Lifesciences Inc. v. Lannett Company, Inc. (D. Del. 2020)

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2020-06-08	1	Complaint	This is an action for patent infringement of U.S. Patent Nos. 9,867,815; 10,016,407; and 10,420,760 (collectively…. 15. United States Patent No. 10,016,407 (the “’407 patent”), titled “Pharmaceutical Compositions… THE PATENTS-IN-SUIT 12. United States Patent No. 9,867,815 (the “’815 patent”), titled…collectively, “the Patents-in-Suit”) under the patent laws of the United States, Title 35, United States…1338 because this is a patent infringement action that arises under the patent laws of the United States	External link to document
2020-07-24	14	Declaration	–18 of U.S. Patent No. 9,867,815; and claims 2–5 and 12–15 of U.S. Patent No. 10,016,407 arising from…2020 20 October 2021 1:20-cv-00770 830 Patent Plaintiff District Court, D. Delaware	External link to document
2020-08-28	28	Brief - Reply	10,016,407 (“the ’407 patent”); and claims 1, 4, 7–12, 15, and 18–20 of U.S. Patent No. 10,420,760 (“… U.S. Patent No. 9,867,815 (“the ’815 patent”); claims 1, 6, 9-11, 16, 19, and 20 of U.S. Patent No. 10,016,407…of the ’815 patent and claims 2–5, and 12–15 of the ’407 patent, (2) the Unasserted Patents, and (3) C-Topical…Genus sued Lannett for patent infringement on specific claims of three patents.1 In response, Lannett …(“the ’760 patent”) (collectively, “the Asserted Patents” and “the Asserted Claims”). 2 Lannett’s Memorandum	External link to document
2020-06-08	3	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,867,815 B1 ;10,016,407 B1 ;10,420,…2020 20 October 2021 1:20-cv-00770 830 Patent Plaintiff District Court, D. Delaware	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.